Hacı Mehmet Türk

Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial

Manish A. Shah, Kohei Shitara, Jaffer A. Ajani et al. · Nature Medicine · 2023 · 450 citations · Full text

Esophageal Cancer, Glow Trial, Cancer Management +16

Bemarituzumab in patients with FGFR2b-selected gastric or gastro-oesophageal junction adenocarcinoma (FIGHT): a randomised, double-blind, placebo-controlled, phase 2 study

Zev A. Wainberg, Peter C. Enzinger, Yoon‐Koo Kang et al. · The Lancet Oncology · 2022 · 201 citations

Surgical Oncology, Esophageal Cancer, Gastrointestinal Oncology +11

Elevated Serum CA-125 Levels in Hemodialysis Patients with Peritoneal, Pleural, or Pericardial Fluids

Alper Sevinç, Süleyman Buyukberber, Hacı Mehmet Türk et al. · Gynecologic Oncology · 2000 · 86 citations

Hemodialysis, Urology, Renal Function +8

Randomized double-blind placebo-controlled phase 2 study of bemarituzumab combined with modified FOLFOX6 (mFOLFOX6) in first-line (1L) treatment of advanced gastric/gastroesophageal junction adenocarcinoma (FIGHT).

Zev A. Wainberg, Peter C. Enzinger, Yoon‐Koo Kang et al. · Journal of Clinical Oncology · 2021 · 76 citations

Immunology, Gastroenterology, Pathology +17

Risk factors of nasopharyngeal carcinoma in Turkey-an epidemiological survey of the Anatolian Society of Medical Oncology.

Fatma Paksoy Türköz, Gökhan Çelenkoğlu, Gamze Gököz Doğu et al. · PubMed · 2011 · 61 citations